All Title Author
Keywords Abstract

PLOS ONE  2013 

Lactate Dehydrogenase 5 Expression in Non-Hodgkin Lymphoma Is Associated with the Induced Hypoxia Regulated Protein and Poor Prognosis

DOI: 10.1371/journal.pone.0074853

Full-Text   Cite this paper   Add to My Lib

Abstract:

Lactate dehydrogenase 5 (LDH-5) is one of the major isoenzymes catalyzing the biochemical process of pyruvate to lactate. The purpose of this study was to investigate the expression of serum LDH-5 and test whether this enzyme is regulated by tumor hypoxia and represents a prognostic marker in patients with Non-Hodgkin’s lymphoma (NHL). In this study, LDH-5 levels were detected using agarose gel electrophoresis in NHL patients (n = 266) and non-NHL controls including benign lymphadenectasis (n = 30) and healthy cohorts (n = 233). We also explored the expression of LDH-5 and hypoxia-inducible factor (HIF) 1α in NHL and benign controls by immunohistochemistry and immunofluorescence staining, respectively. Moreover, the role of LDH-5 in the progression of NHL was assessed by multivariate Cox analyses and Kaplan-Meier survival estimates. Serum concentrations of LDH-5 were significantly higher in NHL patients (9.3%) than in benign patients and healthy controls (7.5% and 7.2%, respectively, P<0.01). Application of LDH-5 detection increased the sensitivity of NHL detection, identifying 53.4% of NHL patients as positive, compared with the measurement of total LDH levels (36.5% sensitivity). LDH-5 concentrations increased with clinical stage, extra-nodal site involvement, and WHO performance status of patients with NHL. Exposure to a hypoxic environment induced the expression of LDH-5 and its overexpression correlated with HIF1α cytoplasmic accumulation in NHL cells. In multivariate analyses, LDH-5 was an independent marker for progression-free survival in patients with NHL (P<0.001). Overall, the expression of LDH-5 was elevated in NHL, showing an association with tumor hypoxia and unfavorable prognosis. Thus, LDH-5 emerges as a promising prognostic predictor for NHL patients.

References

[1]  Prensner JR, Chinnaiyan AM, Srivastava S (2012) Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 29(7): 645–652.
[2]  Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18(6): 598–608.
[3]  Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92(3): 329–333.
[4]  Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66(18): 8927–8930.
[5]  Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S (2012) Increased LDH-5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin Exp Metastasis 30(4): 529–540.
[6]  Rattigan YI, Patel BB, Ackerstaff E, Sukenick G, Koutcher JA, et al. (2012) Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res 318: 326–335.
[7]  Serganova I, Rizwan A, Ni XH, Thakur SB, Vider J, et al. (2011) Metabolic Imaging: A link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin Cancer Res 17: 6250–6261.
[8]  Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Mendrinos S, Sivridis E (2012) The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther 13(13): 1284–1289.
[9]  Armstrong AJ, George DJ, Halabi S (2012) Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 30(27): 3402–3407.
[10]  Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, et al. (2010) Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol 23(1): 45–53.
[11]  Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425–434.
[12]  Kolev Y, Uetake H, Takagi Y, Sugihara K (2008) Lactate Dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-Inducible factor (HIF-1a) pathway, angiogenic factors production and poor prognosis, Ann surg oncol. 15(8): 2336–2344.
[13]  Xue QF, Yeung ES (1996) Determination of lactate dehydrogenase isoenzymes in single lymphocytes from normal and leukemia cell lines. J Chromato B 677: 233–240.
[14]  Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, et al. (2006) Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2 (KDR) pathway and prognosis. Gynecol Oncol 103: 912–918.
[15]  Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, et al. (2003) Lactate dehydrogenase-5 (LDH-5) overexpression in non small-cell lung cancer tissues is linked to tumor hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877–885.
[16]  Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E (2005) Lactate dehydrogenase 5 (LDH-5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22: 25–30.
[17]  Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al.. (2008) WHO classification of tumors of haematopoietic and lymphoid tissues. Int Agen Res Cancer (IARC), ISBN 978–92–8322431–0, Lyon.
[18]  Lu R, Sun M, Feng J, Gao X, Guo L (2011) Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer 11: 270.
[19]  Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, et al. (2001) Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85(6): 881–890.
[20]  Giatromanolaki A, Koukourakis MI, Pezzella F, Sivridis E, Turley H, et al. (2008) Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk Lymph 49(11): 2181–2186.
[21]  Lu RQ, Wu CS, Guo L, Liu YC, Mo W, et al. (2012) The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo. BMC Cancer 12: 607.
[22]  Lu RQ, Pal J, Buon L, Nanjappa P, Shi JL, et al.. (2013) Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: Impact on telomere maintenance, genomic instability, and tumor growth. Oncogene 2013 Apr 22doi:10.1038/onc.2013.103, [Epub ahead of print].
[23]  Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2013. CA Cancer J Clin 62(1): 10–29.
[24]  Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, et al. (2007) German high-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18: 149–157.
[25]  Adida C, Haioun C, Gaulard P, Lepage E, Morel P, et al. (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96: 1921–1925.
[26]  Hecht JR, Trarbach T, Jaeger E (2005) A randomized, double blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving firstline chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23: 16S.
[27]  Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8: 56–61.
[28]  Langhammer S, Najjar M, Hess-Stumpp H, Thierauch KH (2011) LDH-A influences hypoxia-inducible factor 1α (HIF1α) and is critical for growth of HT29 colon carcinoma cells in vivo. Targ Oncol 6: 155–162.
[29]  Guo L, Gao X, Zuo GL (2003) Preliminary evaluation of Serum LDH and its isoenzymes detection in ovarian cancer management. J Diagn Concepts Pract 2(4): 300–302.
[30]  Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, et al. (2003) Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta pathway in HepG2 cells. J Biol Chem 278: 31277–31285.
[31]  Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: strong associationwith survival and activated vascular endothelial growth factor pathway–A report of the tumor angiogenesis research group. J Clin Oncol 24: 4301–4308.
[32]  Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, et al. (1998) Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 394: 485–490.
[33]  Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277: 23111–23115.
[34]  Baker LC, Boult JK, Walker-Samuel S, Chung YL, Jamin Y, et al. (2012) The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumor activity while maintaining vascular function. Br J Cancer 106(10): 1638–1647.
[35]  Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, et al. (2010) Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 5: 22.
[36]  Granchi C, Roy S, Mottinelli M, Nardini E, Campinoti F, et al. (2011) Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. Bioorg Med Chem Lett 21(24): 7331–7336.

Full-Text

comments powered by Disqus